journal article·2025-12

Subcellular two-pronged targeting therapeutics: disrupting mitochondria-endoplasmic reticulum communication in inflammatory disorders

Jianheng Ren, Yuanyi Hua, Zhumei Liao, Xin Wen, Qin Wang

Acta Biomaterialia· Volume 208
Publisher page

Abstract

Researchers have made significant efforts to develop mitochondria or endoplasmic reticulum (ER)-targeting strategies to regulate cellular signaling cascades in inflammatory diseases. Although ER and mitochondria function relatively independently, these organelles can form extensive physical interactions, known as mitochondria-associated ER membranes (MAMs). Emerging evidence suggests that the development of inflammatory diseases depends largely on the pathological crosstalk between mitochondria and ER through MAMs, whereby ER stress and mitochondrial dysfunction collectively activate inflammatory signaling. Due to the presence of MAMs, single-organelle (ER or mitochondria)-specific therapies may not adequately suppress inflammatory signaling activation, highlighting the need for two-pronged strategies to thoroughly interfere with the pathological crosstalk between ER and mitochondria. This review highlights how the interaction between mitochondria and ER contributes to the progression of inflammatory diseases, and systematically summarizes the current advances in delivery strategies for ER and mitochondria targeting. Furthermore, we emphasize the therapeutic potential of simultaneously regulating mitochondrial and ER function to achieve precise control of inflammatory disorders. Our review aims to establish a framework for two-pronged targeting strategies that can restore ER and mitochondrial homeostasis, thereby facilitating the treatment of inflammatory diseases. STATEMENT OF SIGNIFICANCE: Due to the extensively formed mitochondria-associated endoplasmic reticulum (ER) membranes (MAMs) under inflammatory conditions, previous studies focusing on modulating the dysfunction of either mitochondria or ER have demonstrated limited efficacy in inflammatory disorders. MAM-mediated pathological inter-organelles crosstalk can drive the vicious cycle between mitochondria dysfunction and ER stress in inflammatory diseases, underscoring the need for two-pronged approaches that precisely disrupting mitochondria-ER communication. This review highlighted the key role of MAMs in inflammation and summarized recent advances in ER/mitochondria targeted delivery strategies. Furthermore, we underscored the potential therapeutic targets within MAMs for inflammatory intervention, and discussed therapeutic potential of two-pronged approaches in restoring organelle homeostasis and mitigating inflammatory diseases.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Endoplasmic Reticulum Stress and Disease · Autophagy in Disease and Therapy · Calcium signaling and nucleotide metabolism

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. Mitochondrial dynamics and metabolic regulation10.1016/j.tem.2015.12.001 ↗
2. Mitophagy and quality control mechanisms in mitochondrial maintenance10.1016/j.cub.2018.01.004 ↗
3. Mitochondrial drugs10.1016/j.cbpa.2008.06.002 ↗
4. Chemiosmotic coupling: the cost of living10.1038/421583a ↗
5. The endoplasmic reticulum: structure, function and response to cellular signaling10.1007/s00018-015-2052-6 ↗
6. A new perspective on liver diseases: focusing on the mitochondria-associated endoplasmic reticulum membranes10.1016/j.phrs.2024.107409 ↗
7. The role of endoplasmic reticulum–mitochondria-associated membranes in diabetic kidney disease10.1093/cvr/cvad190 ↗
8. Mitochondria-associated membranes (MAMs) and inflammation10.1038/s41419-017-0027-2 ↗
9. ER-to-mitochondria miscommunication and metabolic diseases10.1016/j.bbadis.2015.07.011 ↗
10. Presenilin-2 modulation of ER-mitochondria interactions10.4161/cib.4.3.15160 ↗
11. DJ-1 regulation of mitochondrial function and autophagy through oxidative stress10.4161/auto.7.5.14684 ↗
12. ALS/FTD-associated FUS activates GSK-3β to disrupt the VAPB–PTPIP51 interaction and ER–mitochondria associations10.15252/embr.201541726 ↗
13. PDK4 Augments ER–Mitochondria contact to dampen skeletal muscle insulin signaling during obesity10.2337/db18-0363 ↗
14. Hearts deficient in both Mfn1 and Mfn2 are protected against acute myocardial infarction10.1038/cddis.2016.139 ↗
15. PACS2 is required for ox-LDL-induced endothelial cell apoptosis by regulating mitochondria-associated ER membrane formation and mitochondrial Ca2+ elevation10.1016/j.yexcr.2019.04.002 ↗
16. CerS6-Derived sphingolipids interact with mff and promote mitochondrial fragmentation in obesity10.1016/j.cell.2019.05.008 ↗
17. Activation of TRPV1 channel antagonizes diabetic nephropathy through inhibiting endoplasmic reticulum-mitochondria contact in podocytes10.1016/j.metabol.2020.154182 ↗
18. Novel tumor therapy strategies targeting endoplasmic reticulum-mitochondria signal pathways10.1016/j.arr.2023.101951 ↗
19. STING, the endoplasmic reticulum, and mitochondria: is three a crowd or a conversation?10.3389/fimmu.2020.611347 ↗
20. Role of mitochondria-associated endoplasmic reticulum membrane in inflammation-mediated metabolic diseases10.1155/2016/1851420 ↗
21. A novel endoplasmic reticulum-targeted metal–Organic framework–Confined ruthenium (Ru) nanozyme regulation of oxidative stress for Central post-stroke pain10.1002/adhm.202302526 ↗
22. Engineered mitochondrial ROS scavenger nanocomplex to enhance lung biodistribution and reduce inflammation for the treatment of ARDS10.1007/s42114-024-00989-1 ↗
23. Mitochondria-targeting bimetallic cluster nanozymes alleviate neuropathic pain through scavenging ROS and reducing inflammation10.1002/adhm.202401607 ↗
24. Bioactive nanoenzyme reverses oxidative damage and endoplasmic reticulum stress in neurons under ischemic stroke10.1021/acsnano.1c07205 ↗
25. The in vivo drug delivery pattern of the organelle-targeting small molecules10.1016/j.addr.2023.115020 ↗
26. Mitochondria targeting drugs for neurodegenerative diseases—design, mechanism and application10.1016/j.apsb.2022.03.001 ↗
27. Pharmaceutical strategies for endoplasmic reticulum-targeting and their prospects of application10.1016/j.jconrel.2020.11.054 ↗
28. Targeted drug delivery strategies for precision medicines10.1038/s41578-020-00269-6 ↗
29. Combining nanotechnology with the multifunctional roles of neutrophils against cancer and inflammatory disease10.1039/D1NR07725B ↗
30. Lipophilic triphenylphosphonium cations as tools in mitochondrial bioenergetics and free radical biology10.1007/s10541-005-0104-5 ↗
31. Dysfunctional mitochondria as critical players in the inflammation of autoimmune diseases: potential role in Sjögren’s syndrome10.1016/j.autrev.2021.102867 ↗
32. Mitochondrial ROS
33. new roles of mitochondria10.1042/bio_2022_119 ↗
34. Mitochondrial DNA promotes autoimmunity10.1126/science.aaz9308 ↗
35. Mitochondrial DNA in innate immune responses and inflammatory pathology10.1038/nri.2017.21 ↗
36. The cGAS–STING signaling in cardiovascular and metabolic diseases: future novel target option for pharmacotherapy10.1016/j.apsb.2021.05.011 ↗
37. Reciprocal regulation of mitochondrial fission and fusion10.1016/j.tibs.2020.03.009 ↗
38. Crosstalk between mitochondrial biogenesis and mitophagy to maintain mitochondrial homeostasis10.1186/s12929-023-00975-7 ↗
39. Enzymatic assemblies disrupt the membrane and target endoplasmic reticulum for selective cancer cell death10.1021/jacs.8b04641 ↗
40. Endoplasmic reticulum: a metabolic compartment10.1016/j.febslet.2006.03.050 ↗
41. Direct imaging of ER calcium with targeted-esterase induced dye loading (TED)10.3791/50317-v ↗
42. Calcium signaling10.1016/j.cell.2007.11.028 ↗
43. Ca2+ Fluxes and cancer10.1016/j.molcel.2020.04.017 ↗
44. Calcium dynamics as a machine for decoding signals10.1016/j.tcb.2018.01.002 ↗
45. From endoplasmic-reticulum stress to the inflammatory response10.1038/nature07203 ↗
46. Pharmacological targeting of endoplasmic reticulum stress in disease10.1038/s41573-021-00320-3 ↗
47. A therapeutic target in rheumatoid arthritis?10.1016/j.tips.2018.03.010 ↗
48. The endoplasmic reticulum–mitochondria connection: one touch, multiple functions
49. ER-mitochondria contacts mediate lipid radical transfer via RMDN3/PTPIP51 phosphorylation to reduce mitochondrial oxidative stress10.1038/s41467-025-56666-4 ↗
50. Mediating ER-mitochondrial cross-talk10.1126/science.aaq0141 ↗
51. Endoplasmic reticulum–mitochondria contacts: function of the junction10.1038/nrm3440 ↗
52. ER-mitochondria communication is involved in NLRP3 inflammasome activation under stress conditions in the innate immune system10.1007/s00018-022-04211-7 ↗
53. Mitochondrial control of inflammation10.1038/s41577-022-00760-x ↗
54. Mitochondrial targeted nanomaterials for alleviating inflammation10.1016/j.nantod.2024.102323 ↗
55. Endoplasmic reticulum stress, inflammation, and oxidative stress10.3389/fncel.2014.00213 ↗
56. The interplay between endoplasmic reticulum stress and inflammation10.1038/icb.2011.112 ↗
57. Crosstalk between ER stress, autophagy and inflammation10.3389/fmed.2021.758311 ↗
58. Functional multi-organelle units control inflammatory lipid metabolism of macrophages10.1038/s41556-024-01457-0 ↗
59. Exploring precision treatments in immune-mediated inflammatory diseases: harnessing the infinite potential of nucleic acid delivery10.1002/EXP.20230165 ↗
60. Recent advances in bacteria-based platforms for inflammatory bowel diseases treatment10.1002/EXP.20230142 ↗
61. Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism10.1016/j.jhep.2015.11.022 ↗
62. Research progress on related mechanisms of uric acid activating NLRP3 inflammasome in chronic kidney disease10.1080/0886022X.2022.2036620 ↗
63. Mitofusin 2 (Mfn2) links mitochondrial and endoplasmic reticulum function with insulin signaling and is essential for normal glucose homeostasis10.1073/pnas.1108220109 ↗
64. TGR5 supresses cGAS/STING pathway by inhibiting GRP75-mediated endoplasmic reticulum-mitochondrial coupling in diabetic retinopathy10.1038/s41419-023-06111-5 ↗
65. IP3R1/GRP75/VDAC1 complex mediates endoplasmic reticulum stress-mitochondrial oxidative stress in diabetic atrial remodeling10.1016/j.redox.2022.102289 ↗
66. Inhibition of IP3R/Ca2+ dysregulation protects mice from ventilator-induced lung injury via endoplasmic reticulum and mitochondrial pathways10.3389/fimmu.2021.729094 ↗
67. ER-mitochondria calcium transfer, organelle contacts and neurodegenerative diseases10.1007/978-3-030-12457-1_29 ↗
68. Chronic enrichment of hepatic endoplasmic reticulum–mitochondria contact leads to mitochondrial dysfunction in obesity10.1038/nm.3735 ↗
69. Mitochondria-associated endoplasmic reticulum membrane (MAM) integrity is required for insulin signaling and is implicated in hepatic insulin resistance10.2337/db13-1751 ↗
70. ER-mitochondria tethering complex VAPB-PTPIP51 regulates autophagy10.1016/j.cub.2016.12.038 ↗
71. FUNDC1-dependent mitochondria-associated endoplasmic reticulum membranes are involved in angiogenesis and neoangiogenesis10.1038/s41467-021-22771-3 ↗
72. Ruthenium 360 and mitoxantrone inhibit mitochondrial calcium uniporter channel to prevent liver steatosis induced by high-fat diet10.1111/bph.15767 ↗
73. Triphenylphosphonium decorated liposomes and dendritic polymers: prospective second generation drug delivery systems for targeting mitochondria10.1021/acs.molpharmaceut.6b00237 ↗
74. Ceria nanoparticle systems for selective scavenging of mitochondrial, intracellular, and extracellular reactive oxygen species in Parkinson’s disease10.1002/anie.201805052 ↗
75. Controllable mitochondrial aggregation and fusion by a programmable DNA binder10.1039/D2SC07095B ↗
76. Supramolecular induction of mitochondrial aggregation and fusion10.1021/jacs.0c06783 ↗
77. Mechanism of coupling of oxidative phosphorylation and the membrane potential of mitochondria10.1038/2221076a0 ↗
78. Mitochondrial calcium ion nanogluttons alleviate periodontitis via controlling mPTPs10.1002/adhm.202203106 ↗
79. Localization of mitochondria in living cells with rhodamine 12310.1073/pnas.77.2.990 ↗
80. Mitochondrial gene therapy: advances in Mitochondrial gene cloning, plasmid production, and nanosystems targeted to mitochondria10.1021/acs.molpharmaceut.6b00823 ↗
81. Targeted mitochondrial nanomaterials in biomedicine: advances in therapeutic strategies and imaging modalities10.1016/j.actbio.2024.08.008 ↗
82. Mitochondrial leader sequence-plasmid DNA conjugates delivered into mammalian cells by DQAsomes co-localize with mitochondria10.1016/j.mito.2005.07.001 ↗
83. DQAsomes: a novel potential drug and gene delivery system made from dequalinium™10.1023/A:1011991307631 ↗
84. DQAsome-mediated delivery of plasmid DNA toward mitochondria in living cells10.1016/S0168-3659(03)00297-9 ↗
85. Dequalinium, a topical antimicrobial agent, displays anticarcinoma activity based on selective mitochondrial accumulation10.1073/pnas.84.15.5444 ↗
86. Glycyrrhetinic acid functionalized graphene oxide for mitochondria targeting and cancer treatment in vivo10.1002/smll.201703306 ↗
87. Enhanced reactive oxygen species generation by mitochondria targeting of anticancer drug to overcome tumor multidrug resistance10.1021/acs.biomac.9b00800 ↗
88. Mitochondria as an important target of metformin: the mechanism of action, toxic and side effects, and new therapeutic applications10.1016/j.phrs.2022.106114 ↗
89. Cationic cyclometalated platinum (II) complexes of metformin with self-assembly and AIE behavior as nuclear and mitochondrial targeted anticancer theragnostic agents10.1016/j.dyepig.2024.111971 ↗
90. Mitochondria-targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants10.1096/fj.03-0240fje ↗
91. Mitochondria-targeted peptide antioxidants: novel neuroprotective agents10.1208/aapsj080362 ↗
92. Targeted delivery of PARP inhibitors to neuronal mitochondria via biomimetic engineered nanosystems in a mouse model of traumatic brain injury10.1016/j.actbio.2021.12.023 ↗
93. Mitochondria-penetrating peptides10.1016/j.chembiol.2008.03.015 ↗
94. Peptide-based carbon nanotubes for mitochondrial targeting10.1039/c3nr02694a ↗
95. Cell-penetrating artificial mitochondria-targeting peptide-conjugated metallothionein 1A alleviates mitochondrial damage in Parkinson’s disease models10.1038/s12276-018-0124-z ↗
96. A mitochondria-targeting hetero-binuclear Ir(III)–Pt(II) complex induces necrosis in cisplatin-resistant tumor cells10.1039/C8CC02795A ↗
97. A mitochondria-targeting dinuclear Ir–Ru complex as a synergistic photoactivated chemotherapy and photodynamic therapy agent against cisplatin-resistant tumour cells10.1039/C9CC05998A ↗
98. Responsive and mitochondria -specific ruthenium(ii) complex for dual in vitro applications: two- photon (near-infrared) induced imaging and regioselective cell killing10.1039/c0cc01848a ↗
99. Recent advances on organelle specific Ru(II)/Ir(III)/re(I) based complexes for photodynamic therapy10.1016/j.ccr.2022.214860 ↗
100. A mitochondria-targeted photosensitizer showing improved photodynamic therapy effects under hypoxia10.1002/anie.201604130 ↗